D.A. Davidson & CO. Acquires 7,343 Shares of Bristol-Myers Squibb (NYSE:BMY)

D.A. Davidson & CO. lifted its holdings in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 1.9% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 386,277 shares of the biopharmaceutical company's stock after purchasing an additional 7,343 shares during the quarter. D.A. Davidson & CO.'s holdings in Bristol-Myers Squibb were worth $21,848,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Citizens & Northern Corp lifted its holdings in Bristol-Myers Squibb by 35.7% in the fourth quarter. Citizens & Northern Corp now owns 19,120 shares of the biopharmaceutical company's stock worth $1,081,000 after purchasing an additional 5,026 shares during the period. Truist Financial Corp raised its position in shares of Bristol-Myers Squibb by 3.9% during the 4th quarter. Truist Financial Corp now owns 1,597,150 shares of the biopharmaceutical company's stock worth $90,335,000 after buying an additional 60,365 shares in the last quarter. Wealth Quarterback LLC lifted its stake in shares of Bristol-Myers Squibb by 2.4% in the 4th quarter. Wealth Quarterback LLC now owns 18,927 shares of the biopharmaceutical company's stock worth $1,071,000 after acquiring an additional 443 shares during the period. CIBC Asset Management Inc boosted its holdings in shares of Bristol-Myers Squibb by 3.4% in the fourth quarter. CIBC Asset Management Inc now owns 381,648 shares of the biopharmaceutical company's stock valued at $21,586,000 after acquiring an additional 12,702 shares in the last quarter. Finally, Sanctuary Advisors LLC increased its stake in shares of Bristol-Myers Squibb by 7.0% during the fourth quarter. Sanctuary Advisors LLC now owns 343,064 shares of the biopharmaceutical company's stock valued at $20,289,000 after acquiring an additional 22,388 shares during the period. 76.41% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have weighed in on BMY shares. Truist Financial upped their target price on Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. Leerink Partners raised Bristol-Myers Squibb from a "market perform" rating to an "outperform" rating and raised their target price for the company from $55.00 to $73.00 in a research note on Tuesday, November 12th. Wolfe Research started coverage on Bristol-Myers Squibb in a report on Friday, November 15th. They set a "peer perform" rating on the stock. Leerink Partnrs raised shares of Bristol-Myers Squibb from a "hold" rating to a "strong-buy" rating in a report on Tuesday, November 12th. Finally, Daiwa Capital Markets raised shares of Bristol-Myers Squibb from a "neutral" rating to an "outperform" rating in a research note on Wednesday, November 13th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $57.86.

Insider Activity at Bristol-Myers Squibb

In related news, EVP Samit Hirawat bought 1,823 shares of the firm's stock in a transaction on Friday, February 14th. The stock was bought at an average price of $54.84 per share, with a total value of $99,973.32. Following the purchase, the executive vice president now directly owns 63,932 shares of the company's stock, valued at approximately $3,506,030.88. This represents a 2.94 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.09% of the stock is currently owned by insiders.

Bristol-Myers Squibb Stock Up 0.1 %

NYSE:BMY traded up $0.06 during trading hours on Friday, hitting $55.85. 11,100,311 shares of the stock traded hands, compared to its average volume of 10,886,042. The firm has a market cap of $113.33 billion, a price-to-earnings ratio of -12.63, a PEG ratio of 2.04 and a beta of 0.45. The firm has a 50 day moving average price of $56.99 and a 200 day moving average price of $54.30. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $61.10.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share for the quarter, beating the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. Equities research analysts anticipate that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, February 3rd. Investors of record on Friday, January 3rd were issued a dividend of $0.62 per share. This is a boost from Bristol-Myers Squibb's previous quarterly dividend of $0.60. This represents a $2.48 annualized dividend and a dividend yield of 4.44%. The ex-dividend date of this dividend was Friday, January 3rd. Bristol-Myers Squibb's dividend payout ratio (DPR) is currently -56.11%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.